CAMBRIDGE, Mass., Oct. 13 -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based
Cequent is using the company’s proprietary TransKingdom RNA interference (tkRNAi) technology to develop RNAi-based therapeutics – a new class of drugs designed to work by effectively deactivating the specific gene or genes implicated in the progression of a disease. The company has made considerable progress with its programs targeting polyposis and inflammatory bowel disease (IBD), demonstrating through in vivo testing and studies with non-human primates that its tkRNAi technology can silence target genes successfully. It expects to file its first IND (investigational new drug) application with the U.S. Food and Drug Administration for an orally administered tkRNAi drug targeting the primary oncogene in FAP (familial adenomatous polyposis) before the end of the quarter. FAP is a rare inherited gastrointestinal disease that causes hundreds to thousands of precancerous polyps to form in the colon, leading to colon cancer.
Cequent completed a $15 million Series A financing in June of 2007. Investors included Ampersand Ventures, Pappas Ventures, Yasuda, and the Novartis Option Fund.
2009 BIOCOM Investor Conference
The fourth annual BIOCOM Investor Conference takes place October 26 – 27, 2009, at the Hyatt Regency La Jolla, California. For more information, visit www.biocom.org
About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com)
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders – from inflammatory disease to cancer – based on the company’s proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent’s first products, now entering clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.
SOURCE Cequent Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!